RXRX
Recursion Pharmaceuticals, Inc.
Is RXRX Halal?
AI-driven drug discovery and biotechnology — a generally permissible research business whose current liquidity and income screens fail.
What You Should Know
Recursion uses AI, automation and partnerships to discover and develop medicines. Its March 31, 2026 Form 10-Q reports assets of $1,339.522 million, debt and leases of $72.375 million, cash of $654.473 million, receivables of $13.585 million and quarterly revenue of $6.472 million. Debt/assets is 5.40%, liquidity/assets is 48.86% and receivables plus cash/assets is 49.87%; liquidity and receivables-plus-cash screens fail. The filing reports $5.963 million of interest income, approximately 92.14% of quarterly revenue, reflecting the company's minimal commercial revenue base. No universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Known liquidity/assets is 48.86%, above examined 33.333% limits
- •Receivables-plus-cash/assets is 49.87%, above the examined MSCI 33.33% limit
- •Disclosed interest income is 92.14% of quarterly revenue because product revenue remains minimal; no fixed purification percentage asserted
- •Clinical-stage pipeline and partnership economics require continuing review
- •No universal prohibited-revenue numerator is disclosed
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
72.375 / 1,339.522
654.473 / 1,339.522
668.058 / 1,339.522
5.963 / 6.472
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 48.86%, above the examined 33.333% limit, and disclosed interest income is 92.14% of quarterly revenue; debt/assets is 5.40% and receivables-plus-cash/assets is 49.87%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 48.86%, receivables-plus-cash/assets is 49.87% and disclosed interest income is 92.14%; the examined MSCI limits fail.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 48.86% and the disclosed income ratio is 92.14%, above the examined Malaysia limits. This is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the total-assets liquidity and income screens already fail.
Business-activity disclosure
Recursion uses AI, automation and partnerships to discover and develop medicines. Drug research is generally permissible, while clinical, licensing and customer-use allocation remains qualitative.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator by partnership, clinical workflow or end use.
Purification
Recursion reports $5.963 million of interest income, but no scholar-specific purification percentage or universal prohibited-revenue numerator is provided.
Inputs, assumptions and primary sources
- Amounts are USD millions from Recursion's March 31, 2026 Form 10-Q.
- Debt includes $16.446 million of notes payable and financing-lease liabilities and $55.929 million of operating-lease liabilities.
- Cash and cash equivalents are $654.473 million; restricted cash is excluded and no separate interest-bearing securities balance is disclosed.
- Other receivables are $13.585 million and first-quarter revenue is $6.472 million.
- The filing reports $5.963 million of interest income, primarily from cash and money-market funds, approximately 92.14% of quarterly revenue.
- AI-driven drug discovery and pharmaceutical research are generally permissible, but no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →